Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus

SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria

(2014) Yukihiro Chino et al.   BIOPHARMACEUTICS & DRUG DISPOSITION

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone

(2014) T. Forst et al.   DIABETES OBESITY & METABOLISM

Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus

(2014) S. Sha et al.   DIABETES OBESITY & METABOLISM

Safety and Tolerability of Canagliflozin in Patients With Type 2 Diabetes Mellitus: Pooled Analysis of Phase 3 Study Results

(2014) Keith Usiskin et al.   POSTGRADUATE MEDICINE

Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea

(2013) Guntram Schernthaner et al.   DIABETES CARE

Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial

(2013) F. J. Lavalle-González et al.   DIABETOLOGIA

Hyperuricemia as an Independent Predictor of Vascular Complications and Mortality in Type 2 Diabetes Patients: A Meta-Analysis

(2013) Yili Xu et al.   PLoS One

Hyperuricemia in Young Adults and Risk of Insulin Resistance, Prediabetes, and Diabetes: A 15-Year Follow-up Study

(2012) E. Krishnan et al.   AMERICAN JOURNAL OF EPIDEMIOLOGY

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise

(2012) K. Stenlöf et al.   DIABETES OBESITY & METABOLISM

SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects

(2012) Ele Ferrannini et al.   Nature Reviews Endocrinology

Hyperuricemia Is Independently Associated with Coronary Heart Disease and Renal Dysfunction in Patients with Type 2 Diabetes Mellitus

(2011) Hiroyuki Ito et al.   PLoS One

Management of hyperuricemia in gout: focus on febuxostat

(2010) Mark Reinders et al.   Clinical Interventions in Aging

SLC2A9 Is a High-Capacity Urate Transporter in Humans

(2008) Mark J Caulfield et al.   PLOS MEDICINE